Novel and promising immune checkpoint inhibitors' (ICIs) treatment targeted programmed death 1(PD‐1)/programmed death ligand 1 (PD‐L1) has been revealed a prominent and durable response in approximately 20% NSCLC patients.14 Here, CD274 is linked to non-small cell lung carcinoma.